Hepatitis C-virus - Virus kinetics and resistance mechanisms;Hepatitis-C-virus - Viruskinetik und resistenzmechanismen

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 5, 2004, Pages 387-396

  Herrmann, E ^a,b   Sarrazin, Christoph ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

E2; Hepatitis C; Interferon ; ISDR; Mutations; NS3; NS4A; NS5A; Resistance mechanism; Viral kinetics

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ENZYME INHIBITOR; INTERFERON; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CELL LOSS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; MATHEMATICAL MODEL; REVIEW; VIREMIA; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE; HEPACIVIRUS; HUMANS; INTERFERONS; KINETICS; MODELS, BIOLOGICAL; VIRAL ENVELOPE PROTEINS;

EID: 2642536919     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813128     Document Type: Review

References (95)

1. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492
2. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
3. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
5. Hadziyannis SJ, Dunant H, Sette HJ et al. Peginterferon alfa2a (40 kD) and ribavirin combination therapy in chronic hepatitis C: a randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355
6. Simmonds P. Variability of hepatitis C virus. Hepatology 1995; 21: 570-583
7. Zeuzem S, Schmidt JM, Lee JH et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371
8. Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231
9. Zeuzem S, Schmidt JM, Lee JH et al. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252
10. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107
11. Nguyen TT, Sedghi-Vaziri A, Wilkes LB et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3: 75-78
12. Herrmann E, Lee JH, Marinos G et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37: 1351-1358
13. Bergmann C, Layden JE, Levy-Drummer RS et al. Clinical implications of a new triphasic model of hepatitis C viral kinetics during IFN-alpha therapy. Hepatology 2001; 33 (Suppl): 345A
14. Ribeiro RM, Layden-Almer J, Powers KA et al. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003; 38: 509-517
15. Powers KA, Dixit NM, Ribeiro RM et al. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis 2003; 23 (Suppl 1): 13-18
16. Zhu H, Zhao H, Collins CD et al. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003; 37: 1180-1188
17. Chung RT, He W, Saquib A et al. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci U S A 2001; 98: 9847-9852
18. Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35
19. Layden TJ, Layden JE, Reddy KR et al. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002; 9: 334-339
20. Layden JE, Layden TJ, Reddy KR et al. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase. J Viral Hepat 2002; 9: 340-345
21. Jessner W, Stauber R, Hackl F et al. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 2003; 10: 37-42
22. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-1447
23. Halfon P, Neumann AU, Bourliere M et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat 2003; 10: 351-353
24. Buti M, Sanchez-Avila F, Lurie Y et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-936
25. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23 (Suppl 1): 23-28
26. Pawlotsky JM, Dahari H, Conrad A et al. Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus (HCV) genotype 1b replication kinetics and clearance. Hepatology 1998; 28: 288A
27. Neumann AU, Dahari H, Conrad A et al. Early prediction and mechanismen of the ribavirin/IFN-a dual therapy effect on chronic hepatitis C virus (HCV). Hepatology 1999; 30: 309A
28. Lake-Bakaar G, Ruffini L, Kuzmic P. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. Dig Dis Sci 2003; 48: 126-139
29. Layden-Almer JE, Ribeiro RM, Wiley T et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 1343-1350
30. Berg T, Kaul T, Naumann U et al. Einfluss von Ribavirin auf die Dynamik der Hepatitis-C-Virämie bei Interferon-(-behandelten Patienten mit Response oder Nonresponse. Z Gastroenterol 2000; 38: 881-886
31. Torre F, Giusto R, Grasso A et al. Clearance kinetics of hepatitis C virus under different antiviral therapies. J Med Virol 2001; 64: 455-459
32. Benhamou Y, Hinrichsen H, Sentjens R et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C genotype 1, with advanced liver fibrosis. Hepatology 2002; 36: 304A
33. Hinrichsen H, Benhamou Y, Wedemeyer H et al. First report on the antiviral efficacy of BILN 2061, a novel oral serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Gastroenterology 2004; 126: (in press)
34. Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189
35. De Francesco R, Rice CM. New therapies on the horizon for hepatitis C: re we close? Clin Liver Dis 2003; 7: 211-242, xi
36. Reddy KR, Hoofnagle JH, Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-793
37. McHutchison JG, Poynard T, Pianko S et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119: 1317-1323
38. Layden-Almer JE, Layden TJ. Viral kinetics in hepatitis C virus: special patient populations. Semin Liver Dis 2003; 23 (Suppl 1): 29-33
39. Neumann AU, Reddy KR, Levy-Drummer RS et al. Interferon pharmacokinetics and host factors: Effects on hepatitis C genotype 1 viral kinetics during treatment with consensus interferon. Hepatology 2001; 34: 428A
40. Cotler SJ, Layden JE, Neumann AU et al. First phase hepatitis c viral kinetics in previous nonresponders patients. J Viral Hepat 2003; 10: 43-49
41. Karino Y, Toyota J, Sugawara M et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003; 18: 404-410
42. Torriani FJ, Ribeiro RM, Gilbert TL et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188: 1498-1507
43. Talal AH, Shata MT, Markatou M et al. Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV. J Acquir Immune Defic Syndr 2004; 35: 103-113
44. Gale MJ Jr, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227
45. Taylor DR, Shi ST, Romano PR et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110
46. Foy E, Li K, Wang C et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148
47. Taylor DR, Tian B, Romano PR et al. Hepatitis C virus envelope protein E2 does not inhibit PKR by simple competition with autophosphorylation sites in the RNA-binding domain. J Virol 2001; 75: 1265-1273
48. Gale M Jr, Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18: 5208-5218
49. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81
50. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230
51. Kurosaki M, Enomoto N, Murakami T et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 750-753
52. Komatsu H, Fujisawa T, Inui A et al. Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection. J Med Virol 1997; 53: 361-365
53. Chayama K, Tsubota A, Kobayashi M et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997; 25: 745-749
54. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997; 25: 740-744
55. Khorsi H, Castelain S, Wyseur A et al. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol 1997; 27: 72-77
56. Squadrito G, Leone F, Sartori M et al. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 1997; 113: 567-572
57. Odeberg J, Yun Z, Sonnerborg A et al. Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. J Med Virol 1998; 56: 33-38
58. Chung RT, Monto A, Dienstag JL et al. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol 1999; 58: 353-358
59. Hofgärtner WT, Polyak SJ, Sullivan DG et al. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 1997; 53: 118-126
60. McKechnie VM, Mills PR, McCruden EA. The NS5 a gene of hepatitis C virus in patients treated with interferon-alpha. J Med Virol 2000; 60: 367-378
61. Pawlotsky KM, Germanidis G, Neumann AU et al. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998; 72: 2795-2805
62. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001; 63: 8-16
63. Sarrazin C, Berg T, Lee JH et al. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. J Hepatol 1999; 30: 1004-1013
64. Sarrazin C, Berg T, Lee JH et al. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 2000; 181: 432-441
65. Saiz JC, Lopez-Labrador FX, Ampurdanes S et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis 1998; 177: 839-847
66. Duverlie G, Khorsi H, Castelain S et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998; 79: 1373-1381
67. Nousbaum J, Polyak SJ, Ray SC et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000; 74: 9028-9038
68. Sarrazin C, Herrmann E, Bruch K et al. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 2002; 76: 11079-11090
69. Murakami T, Enomoto N, Kurosaki M et al. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999; 30: 1045-1053
70. Kobayashi M, Watanabe K, Ishigami M et al. Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Am J Gastroenterol 2002; 97: 988-998
71. Sarrazin C, Kornetzky I, Rüster B et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology 2000; 31: 1360-1370
72. Saiz JC, Lopez-Labrador FX, Ampurdanes S et al. The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J Infect Dis 1998; 177: 839-847
73. Abid K, Quadri R, Negro F. Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance. Science 2000; 287: 1555
74. Polyak SJ, Nousbaum JB, Larson AM et al. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. J Infect Dis 2000; 182: 397-404
75. Sarrazin C, Bruckner M, Herrmann E et al. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 2001; 289: 150-163
76. Berg T, Mas MA, Hohne M et al. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 2000; 32: 1386-1395
77. Saito T, Ito T, Ishiko H et al. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol 2003; 98: 1377-1383
78. Watanabe H, Nagayama K, Enomoto N et al. Amino acid substitutions in PKR-elF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res 2003; 26: 268-274
79. Hofmann WP, Sarrazin C, Kronenberger B et al. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. J Infect Dis 2003; 187: 982-987
80. Gerotto M, Dal Pero F, Pontisso P et al. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology 2000; 119: 1649-1655
81. Murphy MD, Rosen HR, Marousek GI et al. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002; 47: 1195-1205
82. Yamamoto C, Enomoto N, Kurosaki M et al. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels. Hepatology 1997; 26: 1616-1620
83. Horiike N, Michitaka K, Masumoto T et al. Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene. J Gastroenterol Hepatol 1999; 14: 345-351
84. Tao Q, Wei L, Chang J et al. Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus. J Gastroenterol 1998; 33: 684-693
85. Sarrazin C, Mihm U, Schönberger B et al. Detection of mutations necessary for HCV replication in the in vitro replicon system in patients with chronic hepatitis C. Journal of Hepatology 2003; 38 (Suppl 2): 169A
86. Paterson M, Laxton CD, Thomas HC et al. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999; 117: 1187-1197
87. Polyak SJ, Paschal DM, McArdle S et al. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999; 29: 1262-1271
88. Song J, Fujii M, Wang F et al. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J Gen Virol 1999; 80 (Pt 4): 879-886
89. Francois C, Duverlie G, Rebouillat D et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol 2000; 74: 5587-5596
90. Polyak SJ, Khabar KS, Paschal DM et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75: 6095-6106
91. Mihm U, Hermann E, Sarrazin U et al. Correlation of serum IL8 levels with virologic response to antiviral therapy in patients with chronic hepatitis C. J Hepatol 2004; 40: 845-852
92. Moradpour D, Kary P, Rice CM et al. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 1998; 28: 192-201
93. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999; 73: 8469-8475
94. Blindenbacher A, Duong FH, Hunziker L et al. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003; 124: 1465-1475
95. Duong FH, Filipowicz M, Tripodi M et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004; 126: 263-277